Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, July 25, 2025

Advances in clinical studies of peptide drugs in stroke disease

 Your competent? doctor has been working on peptides for over a decade, right? Oh NO, INCOMPETENCE REIGNED AND NOTHING WAS DONE, CORRECT?

Let's see EXACTLY HOW LONG AND IN WHAT YOUR DOCTOR IS INCOMPETENT!
  • peptide (16 posts to January 2012)
  • nerinetide (10 posts to February 2020)

    • Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

     November 2024

    Advances in clinical studies of peptide drugs in stroke disease


    https://doi.org/10.1016/j.bbadis.2025.167970Get rights and content

    Highlights

    • •
      Peptide drugs exhibit tremendous potential in stroke treatment, characterized by high specificity, and low toxicity.
    • •
      Multiple peptide drugs (such as CN-105, Nerinetide, and Sovateltide) show promising therapeutic prospects in clinical trials for stroke treatment.
    • •
      Peptide drugs still face challenges in stability, delivery, and bioavailability.
    • •
      Peptide drugs represent an innovative frontier in stroke treatment, offering potential new therapeutic options for patients.

    Abstract

    Stroke remains a leading cause of death and disability globally, with limited treatment options currently available. Fortunately, peptide drugs have emerged as promising candidates for treating central nervous system disorders, including stroke. They offer high specificity, low toxicity, and efficient blood-brain barrier penetration, demonstrating significant therapeutic potential. This review systematically introduces several promising peptide drugs, analyzing their mechanisms, therapeutic efficacy in clinical trials, and potential applications. It also addresses critical challenges in peptide drug development for stroke therapy, such as optimizing dosing strategies, enhancing stability, and improving delivery systems. The analysis of current clinical evidence suggests that peptide-based therapeutics represent a promising frontier in stroke treatment, potentially offering new therapeutic options for patients. This comprehensive review not only highlights the current status of peptide drug development but also provides insights into future directions for advancing stroke therapy.

    Introduction

    Stroke threatens human health and can lead to death and long-term disability [1]. The World Stroke Organization (WSO) stated that stroke is the second reason cause of death globally and the third reason cause of death and disability in its 2022 Global Stroke Fact Sheet [2]. And in 2019, the estimated global cost of stroke exceeded $891 billion, accounting for 1.12 % of the worldwide GDP [2]. The American Heart Association (AHA) also indicated that the prevalence of stroke in the United States is estimated to be 3.3 %, with approximately 9.4 million Americans aged 20 and older self-reporting a history of stroke in its 2023 Stroke Statistics Report [3]. One study suggests an additional 3.4 million adults aged 18 and older would have a stroke in the U.S. by 2030, an increase of 20.5 % from 2012 [2]. The mechanisms of neurological injury in stroke are complex, including cellular mitochondrial dysfunction [4], neuroinflammation [5], excitotoxicity [6], oxidative stress [7], and apoptosis [8]. Current stroke management strategies predominantly rely on time-sensitive interventional approaches, including intravenous thrombolysis (IVT), intra-arterial thrombolysis (IAT), and endovascular thrombectomy (EVT). However, a critically narrow therapeutic window significantly constrains their clinical efficacy [9,10]. That means only a small fraction of stroke patients could get immediate treatment, while the overwhelming majority are precluded from these therapies. This clinical landscape shows the pressing necessity for the development of innovative neuroprotective strategies that can expand the therapeutic window. Consequently, the exploration of targeted neuroprotective agents has become a research priority to mitigate acute neurological damage and provide other effective programs for stroke treatment [11]. This review briefly introduces peptide drugs and summarizes the progress of clinical studies of peptide drugs as neuroprotective agents in stroke.

    Access through your organization

    Posted by at
    Labels: , , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)